6.6
Adrenerge Agonisten: Indirekt wirkende Arzneimittel
Indirekt wirkende adrenerge Agonisten steigern die Wirkung von endogenen Katecholaminen auf verschiedene Weisen, ohne direkt an Adrenozeptoren zu bind…
Indirekt wirkende adrenerge Agonisten verstärken die Wirkung endogener Katecholamine durch unterschiedliche Mechanismen.
Agonisten wie Amphetamin und Tyramin werden als "Verdränger" bezeichnet, da sie die Freisetzung von Katecholaminen induzieren, indem sie ihre Speicher aus dem synaptischen Vesikel erschöpfen.
Sie ähneln Noradrenalin, haben aber keinen Catechol-Anteil. Aufgrund dieser Ähnlichkeit werden sie aktiv in synaptische Gefäße transportiert und ersetzen schließlich Noradrenalin.
Das zytosolische Noradrenalin wird dann gegen ein anderes Verdrängermolekül ausgetauscht und freigesetzt, um auf postsynaptische Adrenozeptoren einzuwirken.
Ein weiterer Mechanismus ist die Hemmung der Katecholamin-Wiederaufnahme. Kokain blockiert den Transporter, der an der Katecholamin-Wiederaufnahme beteiligt ist, und potenziert so die sympathomimetische Wirkung.
Darüber hinaus sind Selegilin – ein MAO-Hemmer – und Entacapon – ein COMT-Hemmer – indirekt wirkende Sympathomimetika, da sie den Stoffwechsel und die anschließende Ausscheidung von zirkulierenden Katecholaminen verhindern.
Indirekt wirkende Agonisten wie Kokain und Amphetamin werden oft aufgrund ihrer zentralen Wirkungen, wie der Euphorie durch die Freisetzung von Dopamin und Serotonin, missbraucht.
View the full transcript and gain access to JoVE Core videos
Q1: How do displacer drugs like amphetamine and tyramine work as indirect-acting agonists?
Displacers resemble noradrenaline but lack a catechol moiety, allowing active transport into synaptic vesicles. Once inside, they replace stored noradrenaline, which is then released to act on postsynaptic adrenoceptors. This mechanism enhances sympathomimetic effects without directly binding to receptors. Amphetamine and tyramine exemplify this displacement strategy.
Q2: What is the mechanism by which cocaine acts as an indirect-acting sympathomimetic?
Cocaine blocks the transporter responsible for catecholamine reuptake, preventing noradrenaline and dopamine from being removed from the synaptic cleft. This potentiates sympathomimetic action by prolonging neurotransmitter availability at adrenoceptors. As a local anesthetic with reuptake-inhibiting properties, cocaine produces both peripheral and central nervous system effects.
Q3: How do MAO inhibitors and COMT inhibitors enhance catecholamine effects?
MAO inhibitors like selegiline and COMT inhibitors like entacapone prevent the breakdown and excretion of circulating catecholamines. By blocking these metabolic pathways, these enzyme inhibitors increase catecholamine concentration and duration of action, indirectly potentiating sympathomimetic responses without directly activating adrenoceptors.
Q4: Why do amphetamine and cocaine have abuse potential despite their pharmacological differences?
Both amphetamine and cocaine stimulate central nervous system effects, particularly dopamine and serotonin release, producing euphoria and reward sensations. Although they use different mechanisms—displacement versus reuptake inhibition—both drugs enhance monoamine availability in the brain, driving their addictive potential and abuse liability.
Q5: What structural feature distinguishes displacer agonists from direct-acting adrenergic agonists?
Displacer agonists like amphetamine and tyramine lack a catechol moiety present in noradrenaline and direct-acting agents. This structural difference enables their active transport into synaptic vesicles, improves oral bioavailability, and enhances central nervous system penetration. The absence of the catechol group is essential to their displacement mechanism.
Q6: How does tyramine in fermented foods interact with MAO inhibitor medications?
Tyramine, a displacer agonist found in fermented foods, mimics sympathetic responses by releasing stored catecholamines. When individuals take MAO inhibitors, tyramine metabolism is blocked, causing excessive accumulation and potentiation of sympathomimetic effects. This interaction can produce dangerous hypertensive responses, making dietary tyramine restriction important during MAO inhibitor therapy.
Q7: What distinguishes indirect-acting agonists from direct-acting agents in their mechanism of action?
Indirect-acting agonists enhance endogenous catecholamine effects through displacement, reuptake inhibition, or enzyme inhibition rather than directly binding to adrenoceptors. Direct-acting agents bind directly to adrenoceptors to produce their effects. Indirect agents potentiate existing neurotransmitter activity, while direct agents independently activate receptors.